Ad26 EBOV vaccine (Crucell/NIH)

N/A

Report date: 2026/05/06 20:02:28

Base Information

Drug NameAd26 EBOV vaccine (Crucell/NIH)
Drug Alias NameAd26埃博拉疫苗 (Crucell/NIH)Ad26.ZEBOV + MVA-BN Filo regimen (Ebola virus infection), Janssen Vaccines & Prevention/NIAIDZabdenoVAC-52150JNJ-61210474
ClassificationVaccines > Application > Prophylactic vaccineVaccines > Development/production technology > Recombinant vector vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsMononegavirales InfectionsHemorrhagic Fever, EbolaRNA Virus Infections +[6] 
Global Approved IndicationsHemorrhagic Fever, Ebola
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2020/07/01
Country/TerritoryUnited StatesUgandaSierra Leone +[16] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesCrucell Holland BvNational Institutes Of Health
China Registration ClassN/A

Develop Information

Active CompaniesInstitut National De La Santé Et De La Recherche Médicale, France U979Institute Of Tropical Medicine AntwerpLondon School Of Hygiene And Tropical Medicine +[6] 
Inactive CompaniesJanssen-Cilag International NvCrucell Holland BvJanssen Pharmaceutical Nv
Active IndicationsMononegavirales InfectionsHemorrhagic Fever, EbolaRNA Virus Infections +[5] 
Inactive IndicationsInfections

Other Information

ATC CodeJ07B
Related LinksWikipedia